Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares some insights into the recent FDA approval of pemigatinib for patients with FGFR1 rearranged relapsed/refractory (R/R) myeloid/lymphoid neoplasms. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.

свернуть